{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T14:47:51Z","timestamp":1766760471238,"version":"3.41.2"},"reference-count":11,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp; Disease"],"published-print":{"date-parts":[[2023,6]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>Anti\u2010MDA5 antibody\u2010positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti\u2010MDA5\u2010positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1\/3 inhibitor tofacitinib as an anti\u2010MDA5\u2010negative treatment option for patients with anti\u2010MDA5\u2010positive DM\u2010ILD.<\/jats:p><\/jats:sec>Method and process<\/jats:title>Here we report a 51\u2010year\u2010old female patient with cough, sputum, shortness of breath for 5 months, rash for 3 months, and muscle pain in the extremities for 1 month. After conventional immunosuppressive therapy plus hormone therapy, the remission was slow. Methylprednisolone was successfully reduced after we administered tofacitinib and tacrolimus. After 132 weeks of follow\u2010up, anti\u2010MDA5 antibody turned negative, clinical symptoms were relieved, and lung Imaging tests were successfully reversed.<\/jats:p><\/jats:sec>Results and Conclusion<\/jats:title>There is currently no report of tofacitinib supplement therapy for anti\u2010MDA5 positive to negative DM. With this case report, tofacitinib is an option for the treatment of anti\u2010MDA5\u2010positive DM\u2010ILD, which deserves attention.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.897","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:55:47Z","timestamp":1686747347000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Successful treatment of anti\u2010MDA5\u2010positive to negative dermatomyositis\u2010associated interstitial lung disease with the JAK inhibitor tofacitinib"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2972-4016","authenticated-orcid":false,"given":"Zong","family":"Jiang","sequence":"first","affiliation":[{"name":"Second Clinical Medical College Guizhou University of Traditional Chinese Medicine guiyang China"},{"name":"Department of Internal Medicine The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine Guiyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Yao","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College Guizhou University of Traditional Chinese Medicine guiyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine Guiyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wukai","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine Guiyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3761"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14128"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.105"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218582"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3634"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2381"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40320"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41602"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57121358"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:07:35Z","timestamp":1748002055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/iid3.897"],"URL":"https:\/\/doi.org\/10.1002\/iid3.897","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"type":"print","value":"2050-4527"},{"type":"electronic","value":"2050-4527"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2023-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e897"}}